Active Ingredient History
Iohexol is a nonionic, water-soluble radiographic contrast medium. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. It is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Drugs which lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with Iohexol. Others include monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs. The most frequently reported adverse reactions are headache, mild to moderate pain including backache, neckache and stiffness, nausea, and vomiting. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Cardiovascular Diseases (approved 1985)
Gastrointestinal Diseases (approved 1985)
Glioma (approved 1985)
Spinal Cord Diseases (approved 1985)
Urologic Diseases (approved 1985)
Abdominal Injuries (Phase 3)
Abdominal Neoplasms (Early Phase 1)
Acute Kidney Injury (Phase 3)
Adenomyosis (Early Phase 1)
Bariatric Surgery (Phase 1/Phase 2)
Breast Neoplasms (Phase 1)
Cardiovascular Diseases (Phase 1)
Contrast Media (Phase 4)
Coronary Artery Disease (Phase 4)
Diabetes Complications (Phase 1/Phase 2)
Diabetes Mellitus (Phase 1/Phase 2)
Diabetes Mellitus, Type 1 (Phase 1/Phase 2)
Diabetes Mellitus, Type 2 (Phase 1/Phase 2)
Diabetic Nephropathies (Phase 1/Phase 2)
Drug Interactions (Phase 1)
Endothelial Cells (Phase 1)
Glomerular Filtration Rate (Phase 1)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 4)
Hormone Replacement Therapy (Phase 4)
Hypothyroidism (Phase 4)
Insulin Resistance (Phase 1)
Kidney Diseases (Phase 4)
Kidney Function Tests (Phase 1)
Leiomyoma (Early Phase 1)
Liver Cirrhosis (Phase 4)
Lung Diseases (Phase 4)
Myocardial Ischemia (Phase 3)
Obesity (Phase 1/Phase 2)
Pediatric Obesity (Phase 1/Phase 2)
Pelvic Neoplasms (Early Phase 1)
Renal Insufficiency (Phase 1)
Sepsis (Phase 4)
Transcatheter Aortic Valve Replacement (Phase 4)
Transgender Persons (Phase 4)
Tuberculosis (Phase 1)
Weight Loss (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
